“So, given that kind of environment, I believe that Indoco Remedies is a stock which is going very cheap, available at cheap valuations and the management is pretty well embedded in the business, they have been around for 30 years,” says Vinit Bolinjkar, Ventura Securities.A view on the pharma space in AstraZeneca, Lupin, Laurus, Zydus … Read more
“In North America, Revlimid is the key contributor and again, speciality drugs for Zydus Lifesciences that will keep on increasing EBITDA margins towards 29-30% and also in the valuation-wise Zydus Life is not trading at much higher valuations like Sun, therefore we feel that Zydus Life is also a second stock which can see good … Read more
Descrease article font size Increase article font size AstraZeneca’s COVID-19 vaccine Vaxzevria is no longer being manufactured or supplied due to declining demand, the company said Wednesday. It is also withdrawing the vaccine’s authorization to be marketed or sold in countries that are part of the European Union, AstraZeneca said. “As multiple variant COVID-19 vaccines … Read more
London: AstraZeneca said on Tuesday it will buy Gracell Biotechnologies for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world’s second-largest pharmaceuticals market. The cash deal, which adds several experimental therapies to AstraZeneca’s portfolio, values Gracell at $2 per ordinary share, or … Read more
